Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma

Cancer Metastasis Reviews
Emiliano CalvoDaniel Castellano

Abstract

The speed at which targeted therapies are being developed and incorporated into the treatment of advanced renal cell carcinoma (RCC) is surprising. After decades in which the only systemic treatment options available for advanced disease were interleukin-2 and interferon-alpha, in the last decade, six new targeted therapies have emerged showing meaningful clinical benefits to patients with advanced RCC through phase III trials. Recently, the Spanish Oncology Genitourinary Group issued its first public statement of recommendations for the optimal management of advanced RCC. However, most pivotal phase III trials on which these recommendations were based have been updated and/or fully reported. Moreover, a new multikinase inhibitor, pazopanib, has emerged with good quality clinical data. In this report, we review in depth the latest phase III data of targeted therapies for advanced RCC and update our recommendations. Furthermore, we hypothesize about the best environment for patients with advanced RCC to receive cancer therapy.

References

Nov 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold F Dvorak
Dec 22, 2004·Current Urology Reports·John S LamArie S Belldegrun
Apr 12, 2005·The Journal of Urology·Hyung L KimRobert A Figlin
Dec 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerBrian I Rini
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Robert J MotzerM Dror Michaelson
Dec 13, 2006·The Journal of Urology·Robert H WeissAllan D Pantuck
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Jan 27, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael B AtkinsLaura King
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Nov 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven B ClauserBryce B Reeve
Dec 21, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tobias KlatteArie S Belldegrun
Apr 22, 2008·The Journal of Urology·Hari S G R Tunuguntla, Merce Jorda
May 9, 2008·International Journal of Cancer. Journal International Du Cancer·Jean-Jacques PatardAllan J Pantuck
Aug 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David CellaRobert J Motzer
Sep 24, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy E Avis
Sep 24, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea BezjakFrances A Shepherd
Oct 7, 2008·Medical Hypotheses·Alex Tabarrok
Jan 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tobias KlatteAllan J Pantuck
Jan 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierRonald M Bukowski
Mar 5, 2009·Cancer Chemotherapy and Pharmacology·Joaquim BellmuntJosé Manuel Trigo
Apr 16, 2009·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Makoto TaharaYoshimasa Hamada
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierRonald M Bukowski
May 29, 2009·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerRobert A Figlin
Jul 21, 2009·The Lancet Oncology·Martin E GoreRonald Bukowski
Jul 21, 2009·The Lancet Oncology·Toni K Choueiri, Joaquim Bellmunt
Aug 5, 2009·The Journal of Infection·D HozborA Graieb
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel Y C HengToni K Choueiri
Jan 1, 2010·Nature Reviews. Drug Discovery·Ronald M BukowskiPeter Kirkpatrick
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cora N SternbergRobert E Hawkins
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniEric J Small

❮ Previous
Next ❯

Citations

Sep 6, 2013·BMC Cancer·Guillermo Villa, Luis-Javier Hernández-Pastor
Aug 2, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Viktor GrünwaldUNKNOWN REACT Study Group

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Robert J MotzerMadhu Mazumdar
The New England Journal of Medicine
Robert J MotzerRobert A Figlin
European Urology
Börje LjungbergEuropean Association of Urology Guideline Group
© 2021 Meta ULC. All rights reserved